

IDA Foundation

IDA Foundation is the world's leading not-for-profit supplier of essential, quality-assured medicines and medical supplies to low- and medium-income countries. Founded in 1972, our purpose is to make quality health-care accessible and affordable for those who are most in need of medicines and medical supplies.

We distribute over 3000 different medicines and medical supplies to over 100 countries. We serve governmental, non-governmental and private organisations, and our customers include Médecines Sans Frontières (MSF), the Clinton Health Access Initiative (CHAI), and the Global Drug Facility (GDF). Quality is central to everything we do, and we continually strive to improve our services, negotiate lower prices, and increase the availability of quality products worldwide.

People

Our people come from all over the world, from diverse educational and professional backgrounds. Our team is bound by passion for our mission; to improve access to and deliver high-quality essential medicines and medical supplies at the lowest possible price to low and medium income countries. Representing 25 nationalities, our regional teams can often serve customers in their native language and are dedicated to finding procurement and supply chain solutions to ensure the road from supplier to patient is as efficient and reliable as possible.

Locations

Headquartered in Amsterdam, we are a global organisation. We have offices in India, China, Nigeria and the U.S., as well as representative agents in over 40 countries.

From the Netherlands, we supply essential medicines directly available from stock. We also facilitate direct, fast, and affordable shipments from other strategically located hubs to provide access to medicines and medical supplies around the world.

Our strong international presence gives us an excellent understanding of local markets to best match your needs with quality guaranteed products and services.



GDP/GMP certified



Making Quality Healthcare Affordable

HIV/AIDS

- Prevention
- Diagnosis
- Treatment
- Monitoring

Contact

IDA Foundation
Slochterweg 35
1027 AA Amsterdam
P.O. Box 37098
1030 AB Amsterdam
The Netherlands

order@idafoundation.org

Check our website for the latest news and product updates
www.idafoundation.org

HIV/AIDS

More than 30 years after the identification of the HIV virus, HIV remains the world's leading infectious killer. It is estimated that 39 million people have died from AIDS-related causes to date. HIV/AIDS is still one of the most fundamental global public health challenges in terms of prevention, diagnosis, treatment and monitoring of the disease.

Great progress has been made in expanding access to antiretroviral therapy (ART) resulting in HIV-positive people living longer, and living healthier and more productive lives. Furthermore, the use of ART has been shown to reduce onward transmission of HIV, preventing new infections.

Efforts to prevent mother-to-child transmission have shown significant results for HIV-positive women and their babies. Worldwide, 7 out of 10 HIV-positive pregnant women received antiretroviral medicines (ARVs) in 2013, which is equal to 970,000 women.

Effective interventions with expectant mothers can reduce the risk of mother-to-child transmission to 2%.

In spite of these accomplishments, much remains to be done. According to WHO, by the end of 2013 11.7 million people in low- and middle-income countries were receiving ART. This number represents only 36% of the 35 million people living with HIV.

IDA Foundation contributes to the global fight against AIDS by increasing access to high quality affordable products for the treatment of HIV/AIDS. Through our relationships with generic and branded suppliers, we are able to source a complete range of antiretrovirals, including first and second line medicines and paediatric formulations. The availability of materials for prevention, diagnosis and monitoring makes IDA a one-stop-shop for comprehensive HIV/AIDS care.

Photo: T. v.d. Leij

Facts

35 million

At the end of 2013, 35 million people globally were living with HIV.

At the end of 2013, only 740,000 of the 3.2 million children living with HIV were receiving ART in low- and middle- income countries.

28 million

Over 28 million people are eligible for antiretroviral therapy, under the updated WHO 2013 consolidated ARV guidelines.

90-90-90

UNAIDS has set ambitious targets for HIV diagnosis, treatment and monitoring.

11.7 million

At the end of 2013, 11.7 million people had access to antiretroviral therapy in low- and middle-income countries.

By 2020:

- 90% of all people living with HIV will have been diagnosed
- 90% of all people with diagnosed HIV infection will receive antiretroviral therapy
- 90% of all people on antiretroviral therapy will have viral suppression (i.e. undetectable amounts of HIV in their blood)

15 million

The member states of the United Nations have set a global target to provide ART to 15 million people by the end of 2015.

Source: World Health Organization (WHO)

Quality

Spanning the entire supply chain, our quality system for medicines includes a comprehensive assessment based on manufacturing site approval, product approval, batch control and verification audits.

Our medical device manufacturers maintain valid ISO 13485 and/or specific ISO requirements. Our products carry a Certificate of Conformity that guarantees a minimum set of regulatory, technical and safety requirements. The certificate also specifies product standards.

Why IDA

Customers choose IDA as their partner in supplying HIV/AIDS related products because they benefit from:

- a one-stop-shop for HIV/AIDS prevention, diagnosis, treatment and monitoring options
- guaranteed high quality products, verified by IDA's Quality Affairs department
- our strong supplier network: reliable sources for continuous supply of quality assured ARVs
- our experience as we supply first, second and third line, and paediatric ARVs to over 40 countries

For more information, or an overview of all HIV/AIDS medicines and supplies available, please contact the IDA Sales Department via order@idafoundation.org

Our Product Range

Prevention

CONDOMS - IDA has a selection of male and female condoms in its product range for the purpose of preventing pregnancy or protecting against sexually transmitted infections.



Condoms

MALE CIRCUMCISION KITS - Voluntary male circumcision is an accepted method of HIV prevention, reducing the risk of female to male sexual transmission of HIV by approximately 60% according to WHO. To support WHO's effort to increase the safety of this procedure, IDA designed a kit that contains all necessary consumable and re-usable devices for male circumcision procedures. This kit can be customised to meet specific customer requirements.

PREP - Pre-exposure prophylaxis (PrEP) promotes the use of daily tenofovir 300mg + emtricitabine 200mg as a prevention option for HIV-negative people who are at high risk of contracting HIV. Studies have shown that both daily and intermittent PrEP can reduce the risk of HIV infection by 86%. PrEP could be a powerful tool in preventing the spread of HIV, especially among marginalised populations who lack access to traditional services.

PEP KITS - The post-exposure prophylactic (PEP) kit contains supplies that reduce the risk of HIV infection in the case of accidental exposure to HIV, whether through a needle-stick or sexual assault. The standard kit contains a short course of antiretroviral treatment, a 1-step urine pregnancy test and emergency contraception. Kit contents can be customized to the customer's needs.

Diagnosis

DIAGNOSTIC TESTS - Our range of cost-effective and user-friendly HIV tests includes rapid diagnostic products that meet country-specific requirements (in line with WHO guidelines on treatment and follow up). IDA is also able to offer early infant diagnostic (EID) tools that can detect HIV in children between 4-6 weeks of age.

Treatment

ANTIRETROVIRAL MEDICINES FROM GENERIC AND BRANDED MANUFACTURERS - We offer a broad assortment of ARV medications for first and second line and paediatric treatment. We monitor medicine developments to ensure that our catalogue reflects current treatment recommendations and that ARVs supplied are USFDA tentatively approved and/or WHO prequalified or are approved in stringent regulated countries.

Our range includes the 5 available types of antiretrovirals:

- Fusion Inhibitors (FI)
- Integrase Inhibitors
- Nucleoside Reverse Transcriptase Inhibitors (NRTI)
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
- Protease Inhibitors (PI)

When possible, we offer fixed dose combinations (FDC), or multiple antiretroviral medicines combined into a single tablet.

MEDICINES TO TREAT OPPORTUNISTIC INFECTIONS (OIs) - People with advanced HIV infection are vulnerable to infections and malignancies that are called 'opportunistic infections' (OIs). The treatment of OIs is an important part of HIV/AIDS care and support. It improves the quality of life for people living with HIV/AIDS and prevents further spread of transmittable OIs to other people.

IDA's range of generic and branded medicines for Opportunistic Infections consists of:

- Anthelmintics
- Antibacterial and antiprotozoal agents
- Anticancer agents
- Antifungal agents
- Antiviral agents

HIV-TB CO-INFECTION TREATMENTS - The treatment for people who are co-infected with HIV and TB is more complicated due to medicines interactions between HIV antiretroviral treatment and TB medication. IDA can supply the complete range of medicines for both HIV/AIDS and TB for treatment programmes for co-infected patients.

Monitoring

Effective management of HIV requires consistent monitoring of a patient's CD4 count and viral load. A CD4 count can indicate when to start a patient on antiretroviral treatment, and viral load monitoring allows a physician to detect a failing medicine regimen and make necessary adjustments. Both CD4 and viral load testing require infrastructure, training, and coordination of reagents and supplies. IDA has experience procuring a number of different CD4 and viral load machines and will work with customers to ensure the appropriate selection and implementation of these critical systems.



Ciprofloxacin



Albendazole chewable